Johnson & Johnson Innovation – JJDC, Inc.

Investing in and supporting the
global entrepreneurial community
alt
About us
jjdc

Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Our portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. 

Strategic

JJDC Year in Review

2021

Learn more about JJDC's recent portfolio activity and strategic investments!

Click here to view newsletter

JJDC finds transformative ideas and helps nurture and mature them into real solutions for today’s patients.

Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations. 

We invest across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from new company creation and seed-level startups to Series A and beyond, including private investments in public equity (PIPEs).

All of our portfolio companies receive the same unwavering commitment. We take a long-term approach, deploying the full capabilities of Johnson & Johnson, one of the world’s largest healthcare companies. This includes early science and technology innovation, clinical development, regulatory affairs, manufacturing, reimbursement strategies and commercialization. All of our portfolio companies receive the same unwavering commitment from us, to translate science and technology into patient benefit.

Our team includes diverse leaders with healthcare and technology expertise and deep R&D, business and investment experience. It’s this insight that helps us understand the needs of entrepreneurs and ensures we can offer the support they need at the right time.

Every opportunity is unique, with tailored roles and terms that provide the best path to success.

Team
Approach

We’re positively impacting human health, identifying the best science and technology and collaborating with innovators across all areas of healthcare.

We’ve Been There Before

Just like you, we are entrepreneurs, scientists and studied risk-takers. Our team’s unique vantage point gives us an exceptional ability to understand your challenges and provide the right kind of help at the right time.

Investing With Impact

We have dedicated teams focused on investing at all stages of innovation, and across the healthcare spectrum: pharmaceuticals, medical devices, consumer health and global public health. We seek innovations with potential to make a transformational impact in the health and lives of people around the globe.

If your early-stage company is looking to advance an idea, connect with one of our Johnson & Johnson Innovation teams located around the globe and led out of the life science hot spots of Shanghai, Boston, San Francisco and London.

Each Investment Is Unique

At JJDC, there’s no such thing as a one-size-fits-all approach. We understand that each idea is unique, requiring an equally distinct investment strategy. We customize every deal to the opportunity, ranging from new company creation, seed and Series A investments in the earliest-stage startups to Series B investments and beyond in more mature companies. We also make private investments in public companies (PIPEs).

We Start at the Source

Collaboration is at the core of our success at JJDC. We partner with entrepreneurs and leading experts to identify and evolve ideas that aim to address the world’s most pressing unmet medical needs. Our offerings bring together the expertise, resources and reach of Johnson & Johnson to cultivate and validate science and technology business models and create and advance new therapeutic options for patients.

Creating Thriving Enterprises

For nearly 50 years, JJDC has made investments in hundreds of innovative companies across pharmaceuticals, medical devices and consumer healthcare. Once we invest, we’re committed to you. We believe in value-added investing and we play an active role in providing strategic direction and enabling access to internal resources and expertise across the Johnson & Johnson Family of Companies.

New Company Creation

Our team stands ready to identify the needs and gaps in the market that are not being addressed for patients around the world and to work with you to create and launch solutions. Through five key stages, we aim to:

  • Discover unmet medical needs and differentiated approaches for meeting them through a patient-centric lens.
  • Validate the idea, confirm its clinical need to secure early feasibility testing, and chart its course from concept to company by leveraging our internal and external scientific and entrepreneurial networks.
  • Create the NewCo by collaborating with the broader innovation ecosystem to identify the best talent, venture syndicate, and optimal business structure/plan.
  • Launch the NewCo to elevate, expand and unleash its full potential.
  • Nurture its success by collaborating with leading investors to support it through key inflection points, with the ultimate goal of improving the health of people around the world.

 

image
Focus Areas

JJDC is seeks ideas that align with our business priorities in our Pharmaceuticals, Consumer and Medical Devices sectors. In each sector, we focus on specific therapeutic areas of interest that have the greatest potential to improve the lives of patients and consumers.

CLICK a business area of interest below

  • Consumer
  • Medical Devices
  • Pharmaceuticals
  • Global Public Health

CLICK on a circle to see the areas we are targeting

  •  
  •  
  •  
 
  •  
    Essential Care
    Essential Care
    Essential Care
  •  
    Acne, Diagnostics & Personalization, Digital Skin Health, Naturals, Skin Rejuvenation
    Skin Health
    Skin Health
  •  
    Allergy, Diagnostics & Personalization, Digital Therapeutics, Naturals & Microbiome, Pain, Smoking Cessation
    Self Care
    Self Care
JJI-JJDC News
05/18/2022

Locus Biosciences Announces $35 Million Financing

03/02/2022

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors

02/25/2022

Biocom conference charts prospects for life sciences industry amid stock market volatility

02/02/2022

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

02/02/2022

Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.

Contact

Make the Connection

We look forward to our first discussion.  If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

contact